Illumina Reports Preliminary Q4 and FY 2025 Results with $4.34 Billion Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Newsfilter
- Q4 Revenue Growth: Illumina's preliminary revenue for Q4 2025 is approximately $1.155 billion, reflecting a 5% increase from Q4 2024, indicating sustained demand and stable growth in the genomics market.
- Ex-China Revenue Performance: The company's revenue outside of China for Q4 2025 is about $1.1 billion, up 7% from Q4 2024, demonstrating the effectiveness of its global expansion strategy and enhancing its competitive position in international markets.
- Stable Earnings Per Share: The GAAP diluted EPS for FY 2025 is expected to be between $2.14 and $2.17, while non-GAAP diluted EPS is projected between $1.27 and $1.30, reflecting the company's stability in profitability and bolstering investor confidence.
- Flat Annual Revenue: Total revenue for FY 2025 is approximately $4.34 billion, flat compared to 2024, showcasing the company's resilience in maintaining revenue stability despite market challenges through effective cost control and product innovation.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 124.12 USD with a low forecast of 40.50 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
